Gambit (Intimacy Stack)
Desire + Response. Two Systems, One Stack.
What It Treats
How It Works
PT-141 (bremelanotide) activates MC3R and MC4R melanocortin receptors in the hypothalamus, generating central sexual desire and arousal signals without hormonal manipulation. Arginine is the substrate for nitric oxide synthase, producing NO that triggers vasodilation and genital blood flow. The central signal (PT-141) and peripheral response (Arginine → NO) work in sequence, matching the body's natural sexual response cascade.
Mechanism of Action
Sexual wellness requires two systems working in concert: desire and arousal in the central nervous system, and blood flow in the peripheral vascular system. Most sexual dysfunction treatments address only one. Gambit addresses both. PT-141 (bremelanotide) activates melanocortin receptors in the hypothalamus — the brain region that generates sexual desire and arousal signals. Unlike PDE5 inhibitors (Viagra, Cialis) which work only on blood flow, PT-141 is FDA-approved specifically for restoring the *desire* side of the equation and works for both men and women. Arginine is the direct precursor to nitric oxide (NO), the molecule that dilates blood vessels and enables genital blood flow — the peripheral response that makes arousal manifest physically. Stacked: PT-141 generates the central signal (desire, arousal, responsiveness), Arginine ensures the peripheral vascular system can respond to that signal. This is why patients who didn't respond to PDE5 inhibitors alone often respond to Gambit — the issue wasn't vascular, it was central signaling.
In two Phase 3 trials of 1,247 premenopausal women with HSDD, bremelanotide (PT-141) 1.75mg on-demand significantly improved sexual desire scores compared to placebo, with 25% of patients achieving a meaningful response. The results led to FDA approval — the first non-hormonal, on-demand treatment for female sexual dysfunction.
Meta-analysis of randomized trials confirmed L-arginine supplementation significantly increases nitric oxide bioavailability and improves endothelium-dependent vasodilation. Effect size was most pronounced in patients with baseline endothelial dysfunction — the population most likely to experience vascular sexual dysfunction.
The Transformation
On the left: the disconnection many patients experience as they age or after hormonal shifts — interest that's lower than it used to be, or interest that exists but doesn't translate into physical response. This is neither purely psychological nor purely mechanical — it's a signaling gap. On the right, after the Gambit protocol: restored central desire response (PT-141 trials showed statistically significant improvements in sexual desire scores in both men and women), plus restored vascular responsiveness (Arginine studies consistently show improved endothelial function and NO-mediated vasodilation). The distinction from single-agent approaches is addressing both the brain and the body simultaneously rather than assuming one is the problem.
Mechanistic review establishing that melanocortin receptor activation in the hypothalamus generates sexual desire and arousal signals independent of androgen, estrogen, or PDE5 pathways. This explained why melanocortin agonists like PT-141 produce sexual response in patients who failed to respond to hormonal or vascular interventions alone.
52-week extension study of bremelanotide showed sustained improvements in sexual desire, arousal, and orgasm function without tachyphylaxis or rebound effect. Discontinuation rate for efficacy loss was minimal, suggesting the central melanocortin mechanism maintains responsiveness over time. Safety profile remained favorable with predominantly mild, transient effects.
Meta-analysis of 16 trials showed L-arginine supplementation (alone or combined with adjuncts) produced statistically and clinically significant improvements in erectile function and subjective sexual satisfaction, with effect sizes largest in patients with baseline endothelial dysfunction. The vascular component of sexual response — often the limiting factor in aging adults — responds well to arginine-driven NO elevation.
What to Expect
On-Demand Initiation
PT-141 on-demand subcutaneous injection 30-45 minutes before anticipated activity + daily arginine. First-use response varies — some patients notice central desire effect immediately; others need 2-3 use cycles.
Vascular Optimization
Arginine's endothelial effects accumulate — NO-mediated vasodilation improves measurably. Central and peripheral systems begin to feel integrated rather than disconnected.
Sustained Response
Both systems functioning consistently. Patients who were non-responders to PDE5 inhibitors alone commonly find a reliable response pattern. Protocol continues as-needed with arginine maintenance.
Your Protocol at a Glance
Ideal For
Adults with libido or arousal concerns that didn't fully respond to hormone optimization alone, patients on SSRIs with sexual side effects, post-menopausal women, and men who found PDE5 inhibitors insufficient (suggesting a central signaling component).
Your Protocol
PT-141 on-demand subcutaneous injection 30-45 minutes before anticipated activity (typically 1-2× per week). Arginine oral or injectable 3-5× per week as daily support. Both scheduled based on patient preference and response.
Safety & Considerations
- Provider supervision required with baseline cardiovascular assessment
- PT-141 can cause transient nausea (most common side effect) and mild blood pressure elevation for 1-2 hours post-injection
- Contraindicated in uncontrolled hypertension, recent cardiovascular events, or severe renal impairment
- Arginine should be used cautiously in patients with active herpes simplex (may promote viral reactivation in susceptible individuals)
- Not intended for use during pregnancy or in active malignancy
Frequently Asked Questions
Yes — PT-141 is FDA-approved specifically for premenopausal women with hypoactive sexual desire disorder, and arginine supports vascular response in women as well. Gambit is designed as a unisex protocol.
PDE5 inhibitors (Viagra, Cialis) work only on blood flow — they address arousal mechanically but do nothing for desire. Gambit addresses both: PT-141 generates the brain signal for desire and arousal, arginine supports the vascular response. This is why it works for patients who didn't fully respond to PDE5 inhibitors alone.
PT-141 is on-demand only (30-45 minutes before anticipated activity, typically 1-2× per week). Arginine is daily as ongoing support. So the "ritual" is much lighter than daily medications.
Yes — hormones set the baseline, Gambit addresses the acute signaling. Many patients on optimized TRT or HRT still experience intermittent desire or arousal gaps; Gambit specifically targets those gaps without requiring hormone dose changes.
Insurance generally does not cover sexual wellness peptide protocols. Our pricing is structured for transparency and predictable monthly cost; consultation fee credits toward the protocol if you proceed.
Ready to Start Gambit (Intimacy Stack)?
Add to your plan and bundle with other services to save 15%. Or book directly.
Cancellation Policy: A $50 non-refundable deposit is required to confirm your appointment for all consultations — our front desk will reach out to collect it after you book. The deposit is applied toward your visit cost. We require at least 24 hours' notice for cancellations or changes. No-shows or late cancellations will forfeit the deposit. By booking, you agree to these terms.
Business hours: Mon–Thu 8am–6pm · Fri 8am–12pm
Explore Other Peptides
BPC-157
TB-500
Tesamorelin
Copper Peptide (GHK-Cu)
Amino Acid Therapy
Arginine
PT-141 (Bremelanotide)
Melanotan
MOTS-c
GLO
KPV
DSIP
High Dose Vitamin C
Venofer (Iron Infusion)
ARA-290
Wolverine (Recovery Stack)
Captain America (Sleep Stack)
Black Widow (Glow Blend)
Iron Man (Body Recomp Stack)
Deadpool (Healing+ Stack)